相关实验视频

Updated: Sep 14, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

低剂量PD-1抑制在复发性/耐药的古典霍奇金淋巴瘤:系统性审查和元分析

Mobil Akhmedov1,2, Pervin Zeynalova3,4, Alexander Fedenko5

  • 1P.A. Hertsen Moscow Oncology Research Institute, branch of the National Medical Radiology Research Center, Moscow, Russian Federation. mobilakhmedov@gmail.com.

Investigational new drugs
|July 21, 2025
PubMed
概括

低剂量PD-1抑制剂在治疗复发性/耐药性经典霍奇金淋巴瘤方面显示出高效率和可接受的安全性. 这种方法可以提高治疗的可访问性,特别是在资源有限的环境中.

关键词:
一定剂量的平板剂量.霍奇金 (Hodgkin) 是一个著名的作家.低剂量的低剂量尼沃卢马布的使用情况佩姆布罗利兹马布的使用方法复发的 复发的 复发的

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

603
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

549

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K